Search

Your search keyword '"Isaacs, C."' showing total 830 results

Search Constraints

Start Over You searched for: Author "Isaacs, C." Remove constraint Author: "Isaacs, C."
830 results on '"Isaacs, C."'

Search Results

1. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.

2. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

4. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

5. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

6. Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.

7. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers

8. 196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2

9. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

10. P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy

11. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

12. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

13. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

14. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

18. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

20. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

21. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

22. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

23. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

25. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

26. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

27. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

28. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

29. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

30. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

31. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

32. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

33. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

34. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

35. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

36. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

38. Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)

39. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

41. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

42. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

43. Shared heritability and functional enrichment across six solid cancers.

44. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4).

45. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

46. Erratum: Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature communications (2019) 10 1 (431))

47. Shared heritability and functional enrichment across six solid cancers

48. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

49. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

50. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Catalog

Books, media, physical & digital resources